133 related articles for article (PubMed ID: 15300194)
1. CDR3 spectratyping identifies clonal expansion within T-cell subpopulations that demonstrate therapeutic antitumor activity.
Kim JA; Rao P; Graor H; Rothchild K; O'keefe C; Maciejewski JP
Surgery; 2004 Aug; 136(2):295-302. PubMed ID: 15300194
[TBL] [Abstract][Full Text] [Related]
2. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
3. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
[TBL] [Abstract][Full Text] [Related]
5. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
Aruga A; Aruga E; Tanigawa K; Bishop DK; Sondak VK; Chang AE
J Immunol; 1997 Jul; 159(2):664-73. PubMed ID: 9218581
[TBL] [Abstract][Full Text] [Related]
6. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
7. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
Kagamu H; Shu S
J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
[TBL] [Abstract][Full Text] [Related]
8. [CDR3 spectratyping and clonal expansion of peripheral blood T cells in a patient with beta-mediterranean anaemia following peripheral blood stem cell transplantation].
Yao XS; Zhou MQ; Ma L; Luo W; Feng XQ; Wen Q; Wang XN
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):529-32. PubMed ID: 18495582
[TBL] [Abstract][Full Text] [Related]
9. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
Plautz GE; Touhalisky JE; Shu S
Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
[TBL] [Abstract][Full Text] [Related]
10. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
[TBL] [Abstract][Full Text] [Related]
11. T-cell receptor beta-chain usage in directly activated alloreactive CD4+ T cells: unrestricted Vbeta gene usage with CDR3 size limitations.
Zhai Y; Kupiec-Weglinski JW
Transplantation; 2003 Feb; 75(4):514-21. PubMed ID: 12605120
[TBL] [Abstract][Full Text] [Related]
12. Skew in T-cell receptor usage and clonal T-cell expansion in patients with chronic rejection of transplanted kidneys.
Matsutani T; Ohashi Y; Yoshioka T; Tsuruta Y; Doi H; Satomi S; Suzuki R
Transplantation; 2003 Feb; 75(3):398-407. PubMed ID: 12589165
[TBL] [Abstract][Full Text] [Related]
13. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
Peng L; Kjaergäard J; Plautz GE; Awad M; Drazba JA; Shu S; Cohen PA
J Immunol; 2002 Nov; 169(9):4811-21. PubMed ID: 12391191
[TBL] [Abstract][Full Text] [Related]
14. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
15. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
Liu Z; Fan H; Wu Y; Chen B
Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
[TBL] [Abstract][Full Text] [Related]
16. T cell receptor Vbeta repertoire usage and clonal expansion of T cells in chronic myelogenous leukemia.
Li YQ; Yang LJ; Chen SH; Zhang YP; Zhang XL; Luo GX
Chin Med J (Engl); 2004 Jun; 117(6):840-3. PubMed ID: 15198883
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of T cell receptor BV dominant usage and CDR3 sequences during acute exacerbation in patients with chronic hepatitis B].
Zhang GW; Yao XS; Ma SW; Yang CG; Yu YC; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2006 Jan; 14(1):23-8. PubMed ID: 16420760
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the CDR3 region of alpha/beta T-cell receptors (TCRs) and TCR BD gene double-stranded recombination signal sequence breaks end in peripheral blood mononuclear cells of T-lineage acute lymphoblastic leukemia.
Xin-Sheng Y; Zheng-Jun X; Li M; Wan-Bang S; Wei-Yang Z; Qian W; Zhi-Ming H; Min-Jie M; Ying L; Zhen-Qiang W; Xiao-Wei H; Ju-Fang W; Xiao-Ning W
Clin Lab Haematol; 2006 Dec; 28(6):405-15. PubMed ID: 17105495
[TBL] [Abstract][Full Text] [Related]
20. [Complementarity-determining region 3 analysis of T cell receptor beta chain variable region in peripheral blood mononuclear cells of patients with systemic lupus erythematosus].
Luo W; Ma L; Yao XS; Zou HY; Wen Q; Ruan GP; Wang XN
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1128-31. PubMed ID: 16939900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
